Skip to main content
. 2023 Jan 16;81(3):224–234. doi: 10.1016/j.jacc.2022.10.030

Central Illustration.

Central Illustration

Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 Trial

In this double-blind, placebo-controlled randomized pilot trial conducted in patients with severe COVID-19, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor reduced the primary endpoint of death or need for intubation and serum interleukin (IL)-6 levels at 30 days compared with placebo. inh = inhibitor; N = number of patients; sc = subcutaneous.